MaxPro Medical
MaxPro Medical
As South Korea continues to solidify its position as a global biotech hub, the demand for Continuous Glucose Monitoring (CGM) systems has surged, driven by a sophisticated National Health Insurance (NHI) reimbursement framework and an increasingly health-conscious aging population. The Korean medical device market is characterized by high entry barriers regarding MFDS (Ministry of Food and Drug Safety) compliance, making strategic partnerships between manufacturers and local distributors essential.
Korea has one of the highest rates of smartphone penetration globally, which has accelerated the adoption of App-based CGM solutions. Local clinics in Seoul, Busan, and Incheon are increasingly integrating CGM data into EMR (Electronic Medical Record) systems for "Smart Hospital" initiatives.
Exporting to Korea requires strict adherence to KGMP (Korea Good Manufacturing Practice). Our manufacturing facilities are ISO 13485 certified, providing the foundational reliability required for seamless MFDS registration and market entry.
The industry is moving toward "Calibration-free" sensors with a Mean Absolute Relative Difference (MARD) of below 10%. Our next-gen sensors focus on ultra-low power consumption and biocompatible adhesive patches optimized for diverse skin types.
Founded in 2009, Shenzhen MaxPro Medical Co., Ltd. is a leading manufacturer specializing in advanced medical devices and chronic disease monitoring solutions. We provide the "Information Gain" that procurement officers need—moving beyond simple supply to comprehensive clinical data integration.
Our commitment to Experience, Expertise, Authoritativeness, and Trustworthiness (E-E-A-T) is reflected in our modern 20,000 sq ft manufacturing facility. Certified under ISO 13485, our products comply with international medical regulations, with key sensors receiving FDA 510(k) and CE certification. We don't just sell hardware; we provide a validated clinical pathway for metabolic health.
For global procurement managers in Korea, the focus has shifted from "Lowest Cost" to "Total Value of Ownership." Our CGM systems offer:
By 2026, the Korean CGM market is expected to integrate with "Digital Therapeutics" (DTx). Our R&D is currently focused on non-invasive sensing and multi-analyte monitors (Glucose + Lactate + Ketones) to provide a 360-degree view of metabolic health.
Explore our R&D Pipeline →Our flagship 15-day CGM system maintains a Mean Absolute Relative Difference (MARD) of under 9.2%, ensuring high clinical accuracy that rivals top-tier global brands.
We provide a complete "Regulatory Technical File" for our Korean partners, including clinical trial data, biocompatibility reports, and KGMP documentation to expedite the MFDS approval process.
Yes, we offer open API and SDK options for local hospital groups in Korea to integrate glucose data directly into their existing digital health platforms.
MOQs vary based on customization needs. We offer flexible solutions for both large-scale national distributors and specialized private-label clinics.
Strict quality management systems from raw material sourcing to final product inspection.
Dedicated technical support teams providing fast and professional assistance globally.
A professional R&D team continuously improving sensor longevity and app connectivity.
